Team:Paris/safety

From 2009.igem.org

(Difference between revisions)
(→Safety)
m (→Overview)
Line 6: Line 6:
As an emerging technology, Synthetic Biology raises new technical and scientific challenges but also questions for ethics, biosafety, biosecurity and intellectual property.
As an emerging technology, Synthetic Biology raises new technical and scientific challenges but also questions for ethics, biosafety, biosecurity and intellectual property.
-
As one of the stakeholder of Synthetic biology, our team lead a open-discussion at the Lab about these questions. You can find our work in the wiki in [[https://2009.igem.org/Team:Paris/Ethics_overview#top Ethic part]].
+
As one of the stakeholder of Synthetic biology, our team lead a open-discussion at the Lab about these questions. You can find our work in the wiki in [[https://2009.igem.org/Team:Paris/Ethics_overview#top Ethic part]] or directly in [[https://static.igem.org/mediawiki/2009/b/b2/TeamParis-SynthEthics.pdf SynthEthics.pdf]].
 +
After these general purposes, we will now summarize questions/answers focused on biosafety.
 +
<html>
 +
<body>
 +
<center>
<iframe src="http://docs.google.com/present/embed?id=dszgzt9_236dv4ncqcs&autoStart=true&loop=true" frameborder="0" width="410" height="342"></iframe>
<iframe src="http://docs.google.com/present/embed?id=dszgzt9_236dv4ncqcs&autoStart=true&loop=true" frameborder="0" width="410" height="342"></iframe>
 +
</center>
 +
</body>
 +
<html>
===Safety===
===Safety===
-
The work has been carried out in the laboratory of Molecular, Evolutive and Medical Genetics Unit (U571) of the French National Institute of Medical Research (INSERM) within the Paris Descartes University's Medical faculty. Thus, the work was inspected both by the University's Safety officer (last surprise visit 18 Oct went smoothly with the only caveat being paper boxes on ther top shelf above the bench that needed to be removed...). More importantly, the biosafety officer of our unit followed our work.
+
 
 +
 
 +
'''local biosafety overview '''
 +
 
 +
The work has been carried out in the laboratory of Molecular, Evolutive and Medical Genetics Unit (U571, also know as [[http://www.necker.fr/tamara/ TaMaRa's lab]]) of the French National Institute of Medical Research ([[http://www.inserm.fr/index.php INSERM]]) within the [[http://www.medecine.univ-paris5.fr Paris Descartes University's Medical faculty]]. Thus, the work was inspected both by the University's Safety officer (last surprise visit 18 Oct went smoothly with the only caveat being paper boxes on ther top shelf above the bench that needed to be removed...). More importantly, the biosafety officer of our unit followed our work.
 +
 
Both institutions have their ethical committees though no specific issue concerning our project needed to be raised. Nonetheless, a thorough work was done throughout this period regarding general safety and ethical issues not only specific to our work (including declining other ideas of projects that might have had potential future hazard). This is detailed within the Ethics part of our wiki documentation. Click here for more [[https://2009.igem.org/Team:Paris/Ethics_overview#Ethics_:_Overview  Ethics and Biosafety]]
Both institutions have their ethical committees though no specific issue concerning our project needed to be raised. Nonetheless, a thorough work was done throughout this period regarding general safety and ethical issues not only specific to our work (including declining other ideas of projects that might have had potential future hazard). This is detailed within the Ethics part of our wiki documentation. Click here for more [[https://2009.igem.org/Team:Paris/Ethics_overview#Ethics_:_Overview  Ethics and Biosafety]]
 +
'''Safety issues raise by our ideas'''
Draft idea
Draft idea
Line 27: Line 40:
our role  after iGEM competition
our role  after iGEM competition
 +
 +
 +
  1. Would any of your project ideas raise safety issues in terms of:
 +
          * researcher safety,
 +
          * public safety, or
 +
          * environmental safety?
 +
  2. Is there a local biosafety group, committee, or review board at your institution?
 +
  3. What does your local biosafety group think about your project?
 +
  4. Do any of the new BioBrick parts that you made this year raise any safety issues?
 +
          * If yes, did you document these issues in the Registry?

Revision as of 03:07, 22 October 2009

iGEM > Paris > Home > Safety

Overview

As an emerging technology, Synthetic Biology raises new technical and scientific challenges but also questions for ethics, biosafety, biosecurity and intellectual property. As one of the stakeholder of Synthetic biology, our team lead a open-discussion at the Lab about these questions. You can find our work in the wiki in [Ethic part] or directly in [SynthEthics.pdf].

After these general purposes, we will now summarize questions/answers focused on biosafety.

===Safety=== '''local biosafety overview ''' The work has been carried out in the laboratory of Molecular, Evolutive and Medical Genetics Unit (U571, also know as [[http://www.necker.fr/tamara/ TaMaRa's lab]]) of the French National Institute of Medical Research ([[http://www.inserm.fr/index.php INSERM]]) within the [[http://www.medecine.univ-paris5.fr Paris Descartes University's Medical faculty]]. Thus, the work was inspected both by the University's Safety officer (last surprise visit 18 Oct went smoothly with the only caveat being paper boxes on ther top shelf above the bench that needed to be removed...). More importantly, the biosafety officer of our unit followed our work. Both institutions have their ethical committees though no specific issue concerning our project needed to be raised. Nonetheless, a thorough work was done throughout this period regarding general safety and ethical issues not only specific to our work (including declining other ideas of projects that might have had potential future hazard). This is detailed within the Ethics part of our wiki documentation. Click here for more [[https://2009.igem.org/Team:Paris/Ethics_overview#Ethics_:_Overview Ethics and Biosafety]] '''Safety issues raise by our ideas''' Draft idea on n a pas commander de sequence toxique on a eu des idées touchant biosafety : meningtis ou deinoccocus risk assesment in synthetic biology impcat de la modelisation our role after iGEM competition 1. Would any of your project ideas raise safety issues in terms of: * researcher safety, * public safety, or * environmental safety? 2. Is there a local biosafety group, committee, or review board at your institution? 3. What does your local biosafety group think about your project? 4. Do any of the new BioBrick parts that you made this year raise any safety issues? * If yes, did you document these issues in the Registry?

Retrieved from "http://2009.igem.org/Team:Paris/safety"